Literature DB >> 20494390

Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection.

Rebecca M Lynch1, Rong Rong, Bing Li, Tongye Shen, William Honnen, Joseph Mulenga, Susan Allen, Abraham Pinter, S Gnanakaran, Cynthia A Derdeyn.   

Abstract

The V3 region of the HIV-1 envelope (Env) glycoprotein gp120 is a key functional domain yet it exhibits distinct mutational patterns across subtypes. Here an invariant residue (Ile 309) was replaced with Leu in 7 subtype C patient-derived Envs from recent infection and 4 related neutralizing antibody escape variants that emerged later. For these 11 Envs, I309L did not alter replication in primary CD4 T cells; however, replication in monocyte-derived macrophages was enhanced. Infection of cell lines with low CD4 or CCR5 revealed that I309L enhanced utilization of CD4 but did not affect the ability to use CCR5. This CD4-enhanced phenotype tracked with sensitivity to sCD4, indicating increased exposure of the CD4 binding site. The results suggest that Ile 309 preserves a V3-mediated masking function that occludes the CD4 binding site. The findings point to an immune evasion strategy in subtype C Env to protect this vulnerable immune target. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494390      PMCID: PMC3987868          DOI: 10.1016/j.virol.2010.04.010

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  79 in total

1.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

2.  Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4.

Authors:  J P Moore; L C Burkly; R I Connor; Y Cao; R Tizard; D D Ho; R A Fisher
Journal:  AIDS Res Hum Retroviruses       Date:  1993-06       Impact factor: 2.205

3.  Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1.

Authors:  B T Korber; K MacInnes; R F Smith; G Myers
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

5.  Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.

Authors:  D Kabat; S L Kozak; K Wehrly; B Chesebro
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

6.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression.

Authors:  D D Richman; S A Bozzette
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

7.  Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.

Authors:  R L Willey; M A Martin; K W Peden
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion.

Authors:  Elaine R Thomas; Rebecca L Dunfee; Jennifer Stanton; Derek Bogdan; Joann Taylor; Kevin Kunstman; Jeanne E Bell; Steven M Wolinsky; Dana Gabuzda
Journal:  Virology       Date:  2006-11-07       Impact factor: 3.616

9.  Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.

Authors:  R I Connor; K E Sheridan; D Ceradini; S Choe; N R Landau
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

10.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  18 in total

1.  A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.

Authors:  Thomas Musich; Paul J Peters; Maria José Duenas-Decamp; Maria Paz Gonzalez-Perez; James Robinson; Susan Zolla-Pazner; Jonathan K Ball; Katherine Luzuriaga; Paul R Clapham
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

2.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

3.  Individuals with HIV-1 Subtype C Infection and Cryptococcal Meningitis Exhibit Viral Genetic Intermixing of HIV-1 Between Plasma and Cerebrospinal Fluid and a High Prevalence of CXCR4-Using Variants.

Authors:  Katlego Sojane; Richard T Kangethe; Christina C Chang; Mahomed-Yunus S Moosa; Sharon R Lewin; Martyn A French; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2018-05-23       Impact factor: 2.205

Review 4.  Structure-based vaccine design in HIV: blind men and the elephant?

Authors:  Robert Pejchal; Ian A Wilson
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

5.  Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

Authors:  Aidy Salomon; Chavdar Krachmarov; Zhong Lai; William Honnen; Barry S Zingman; Julie Sarlo; Miroslaw K Gorny; Susan Zolla-Pazner; James E Robinson; Abraham Pinter
Journal:  Virology       Date:  2013-11-12       Impact factor: 3.616

6.  Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.

Authors:  Katie M Kilgore; Megan K Murphy; Samantha L Burton; Katherine S Wetzel; S Abigail Smith; Peng Xiao; Sharmila Reddy; Nicholas Francella; Donald L Sodora; Guido Silvestri; Kelly S Cole; Francois Villinger; James E Robinson; Bali Pulendran; Eric Hunter; Ronald G Collman; Rama R Amara; Cynthia A Derdeyn
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

7.  A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence.

Authors:  Sarah Welbourn; Srirupa Chakraborty; Jie E Yang; Anne S Gleinich; Sailaja Gangadhara; Salar Khan; Courtney Ferrebee; Bhrugu Yagnik; Samantha Burton; Tysheena Charles; S Abigail Smith; Danielle Williams; Rohini Mopuri; Amit A Upadhyay; Justin Thompson; Matt A Price; Shiyu Wang; Zhaohui Qin; Xiaoying Shen; LaTonya D Williams; Nathan Eisel; Tiffany Peters; Lu Zhang; William Kilembe; Etienne Karita; Georgia D Tomaras; Steven E Bosinger; Rama R Amara; Parastoo Azadi; Elizabeth R Wright; Sandrasegaram Gnanakaran; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2022-05-03       Impact factor: 6.823

8.  Envelope diversity, characteristics of V3 region and predicted co-receptor usage of human immunodeficiency viruses infecting north Indians.

Authors:  Raiees Andrabi; Rajesh Kumar; Manju Bala; Ambili Nair; Prakash Ss; Vandana Kushwaha; Kalpana Luthra
Journal:  J Microbiol       Date:  2012-11-04       Impact factor: 3.422

9.  Longitudinal HIV-1 gp120-C2V3C3 phylogenetic surveillance and tropism evolution in patients under HAART.

Authors:  Franco A Moretti; Manuel Gómez-Carrillo; Jorge F Quarleri
Journal:  Virus Genes       Date:  2013-03-06       Impact factor: 2.332

10.  The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.

Authors:  Savrina Manhas; Dennis Chau; Caitlin Rempel; Brenda E Clark; Kate Auyeung; Ralph Pantophlet
Journal:  Virology       Date:  2014-06-25       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.